Hyperpolarized
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bone Neoplasms
/ drug therapy
Carbon Isotopes
/ analysis
Carboplatin
/ administration & dosage
Docetaxel
/ administration & dosage
Feasibility Studies
Follow-Up Studies
Humans
Liver Neoplasms
/ drug therapy
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Pilot Projects
Prognosis
Prostatic Neoplasms
/ drug therapy
Pyruvic Acid
/ metabolism
Survival Rate
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
21
08
2019
accepted:
18
10
2019
revised:
10
10
2019
pubmed:
7
11
2019
medline:
9
3
2021
entrez:
6
11
2019
Statut:
ppublish
Résumé
Hyperpolarized (HP) Six patients who had metastatic castration-resistant prostate cancer were recruited. Carbon-13 MR examination were conducted on a clinical 3T MRI following injection of 250 mM hyperpolarized We observed a high rate of glycolytic metabolism in prostate cancer metastases, with a mean k HP
Sections du résumé
BACKGROUND
Hyperpolarized (HP)
METHODS
Six patients who had metastatic castration-resistant prostate cancer were recruited. Carbon-13 MR examination were conducted on a clinical 3T MRI following injection of 250 mM hyperpolarized
RESULTS
We observed a high rate of glycolytic metabolism in prostate cancer metastases, with a mean k
CONCLUSIONS
HP
Identifiants
pubmed: 31685983
doi: 10.1038/s41391-019-0180-z
pii: 10.1038/s41391-019-0180-z
pmc: PMC7196510
mid: NIHMS1059383
doi:
Substances chimiques
Carbon Isotopes
0
Docetaxel
15H5577CQD
Pyruvic Acid
8558G7RUTR
Carboplatin
BG3F62OND5
Carbon-13
FDJ0A8596D
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
269-276Subventions
Organisme : NIBIB NIH HHS
ID : P41 EB013598
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA166655
Pays : United States
Organisme : NIBIB NIH HHS
ID : U01 EB026412
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA183071
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA183071, R01CA215694, R01CA166655, U01CA232320
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA232320
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215694
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Society AC. Cancer facts and figures 2019. Atlanta, GA: American Cancer Society; 2019.
Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, et al. Rationale for modernising imaging in advanced prostate cancer. Eur Urol Focus. 2017;3:223–39.
doi: 10.1016/j.euf.2016.06.018
James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67:1028–38.
doi: 10.1016/j.eururo.2014.09.032
Goodman OB Jr., Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:34–9.
doi: 10.1038/pcan.2013.41
Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65:270–3.
doi: 10.1016/j.eururo.2013.10.055
Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36:2492–503.
doi: 10.1200/JCO.2017.77.6880
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26:1148–59.
doi: 10.1200/JCO.2007.12.4487
O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol. 2015;7:202–11.
doi: 10.4329/wjr.v7.i8.202
Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med. 2017;58:81–4.
doi: 10.2967/jnumed.116.181800
Seitz AK, Rauscher I, Haller B, Krönke M, Luther S, Heck MM, et al. Preliminary results on response assessment using 68 Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2018;45:602–12.
doi: 10.1007/s00259-017-3887-x
Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PEZ, Harzstark AL, Ferrone M, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-C-13]Pyruvate. Sci Transl Med. 2013;5:198ra108
Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci USA. 2003;100:10158–63.
doi: 10.1073/pnas.1733835100
Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, et al. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008;68:8607–15.
doi: 10.1158/0008-5472.CAN-08-0749
Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson JA, Brindle K, Cunningham CH, et al. Hyperpolarized (13)C MRI: path to clinical translation in oncology. Neoplasia. 2018;21:1–16.
doi: 10.1016/j.neo.2018.09.006
Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011;71:6921–5.
doi: 10.1158/0008-5472.CAN-11-1457
Kim JW, Dang CV. Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66:8927–30.
doi: 10.1158/0008-5472.CAN-06-1501
Gonzalez PS, O’Prey J, Cardaci S, Barthet VJA, Sakamaki JI, Beaumatin F, et al. Mannose impairs tumour growth and enhances chemotherapy. Nature. 2018;563:719–23.
doi: 10.1038/s41586-018-0729-3
Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, et al. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer. 2010;9:33.
doi: 10.1186/1476-4598-9-33
Timm KN, Kennedy BW, Brindle KM. Imaging tumor metabolism to assess disease progression and treatment response. Clin Cancer Res. 2016;22:5196–203.
doi: 10.1158/1078-0432.CCR-16-0159
Aggarwal R, Vigneron DB, Kurhanewicz J. Hyperpolarized 1-[(13)C]-pyruvate magnetic resonance imaging detects an early metabolic response to androgen ablation therapy in prostate cancer. Eur Urol. 2017;72:1028–9.
doi: 10.1016/j.eururo.2017.07.022
Chen HY, Larson PEZ, Gordon JW, Bok RA, Ferrone M, van Criekinge M, et al. Technique development of 3D dynamic CS-EPSI for hyperpolarized (13) C pyruvate MR molecular imaging of human prostate cancer. Magn Reson Med. 2018;80:2062–72.
doi: 10.1002/mrm.27179
Park I, Larson PEZ, Gordon JW, Carvajal L, Chen HY, Bok R, et al. Development of methods and feasibility of using hyperpolarized carbon-13 imaging data for evaluating brain metabolism in patient studies. Magn Reson Med. 2018;80:864–73.
doi: 10.1002/mrm.27077
Brender JR, Kishimoto S, Merkle H, Reed G, Hurd RE, Chen AP, et al. PET by MRI: Glucose Imaging by 13C-MRS without dynamic nuclear polarization by noise suppression through tensor decomposition rank reduction. bioRxiv. 2018; preprint 15 February 2018; https://doi.org/10.1101/265793 .
Nelson SJ, Brown TR. The accuracy of quantification from 1d nmr-spectra using the piqable algorithm. J Magn Reson. 1989;84:95–109.
Larson PEZ, Chen HY, Gordon JW, Korn N, Maidens J, Arcak M, et al. Investigation of analysis methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients. NMR Biomed. 2018;31:e3997.
doi: 10.1002/nbm.3997
Korn N, Larson PEZ, Chen H-Y, Gordon JW, Bok RA, Van Criekinge M, et al. The rate of hyperpolarized [1-13C] pyruvate to [1-13C] lactate conversion distinguishes high-grade prostate cancer from low-grade prostate cancer and normal peripheral zone tissue in patients. Proceedings of the 26th Annual Meeting of ISMRM, Paris France. 2018; International Society for Magnetic Resonance in Medicine.
Mammoli D, Gordon J, Autry A, Larson PEZ, Li Y, Chen HY, et al. Kinetic modeling of hyperpolarized carbon-13 pyruvate metabolism in the human brain. IEEE Trans Med Imaging. 2019; e-pub ahead of print 2 July 2019; https://doi.org/10.1109/TMI.2019.2926437 .
Bok R, Lee J, Sriram R, Keshari K, Sukumar S, Daneshmandi S, et al. The role of lactate metabolism in prostate cancer progression and metastases revealed by dual-agent hyperpolarized (13)C MRSI. Cancers. 2019;11:257.
Hiew K, Hart CA, Ali A, Elliott T, Ramani V, Sangar V, et al. Primary mutational landscape linked with pre-docetaxel lactate dehydrogenase levels predicts docetaxel response in metastatic castrate-resistant prostate cancer. Eur Urol Focus. 2019;5:831–41.
Koukourakis MI, Giatromanolaki A, Panteliadou M, Pouliliou SE, Chondrou PS, Mavropoulou S, et al. Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. Br J Cancer. 2014;110:2217–23.
doi: 10.1038/bjc.2014.158
Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, et al. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol Oncol. 2018;1:78–82.
doi: 10.1016/j.euo.2018.03.010
Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, et al. PSMA Ligands for PET imaging of prostate cancer. J Nucl Med. 2017;58:1545–52.
doi: 10.2967/jnumed.117.191031
Heiken JP, Bae KT. Contrast medium administration and scan timing for MDCT. In: Marchal G, Vogl TJ, Heiken JP, Rubin GD (eds). Multidetector-Row Computed Tomography, Springer: New York 2005, pp 13–20.
Davnall F, Yip CS, Ljungqvist G, Selmi M, Ng F, Sanghera B, et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging. 2012;3:573–89.
doi: 10.1007/s13244-012-0196-6
Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266–76.
doi: 10.1093/jnci/93.4.266
Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487–95.
doi: 10.1158/2159-8290.CD-11-0130
Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 2014;15:1521–32.
doi: 10.1016/S1470-2045(14)71021-6
Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766–74.
doi: 10.1007/s00259-008-0788-z
Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253–8.
doi: 10.1007/s00259-005-1842-8
Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375–9.
doi: 10.1200/JCO.1998.16.10.3375
Todenhofer T, Stenzl A, Hofbauer LC, Rachner TD. Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. Int J Endocrinol. 2015;2015:838202.
doi: 10.1155/2015/838202
Autry AW, Gordon JW, Carvajal L, Mareyam A, Chen HY, Park I, et al. Comparison between 8‐and 32‐channel phased‐array receive coils for in vivo hyperpolarized 13C imaging of the human brain. Magn Reson Med. 2019;82:833–41.
doi: 10.1002/mrm.27743
Gordon JW, Chen HY, Autry A, Park I, Van Criekinge M, Mammoli D, et al. Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients. Magn Reson Med. 2019;81:2702–9.
Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol. 2011;60:935–43.
doi: 10.1016/j.eururo.2011.07.060
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446–53.
doi: 10.1200/JCO.2017.75.4853
Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: reality or figment of imagination? Cancer. 2019;125:340–52.
doi: 10.1002/cncr.31860
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–42.
doi: 10.1016/j.eururo.2016.08.002